Advertisement

Pediatric Nephrology

, Volume 27, Issue 5, pp 765–771 | Cite as

Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil

  • Yue DuEmail author
  • Ling Hou
  • Chengguang Zhao
  • Mei Han
  • Yubin Wu
Original Article

Abstract

Background

Henoch–Schönlein purpura (HSP) can progress to Henoch–Schönlein purpura nephritis (HSPN), and the most effective management remains unclear. Our aim was to evaluate the efficacy of mycophenolate mofetil (MMF) for treating pediatric patients with HSPN and nephrotic-range proteinuria.

Methods

Twelve children, seven boys and five girls, mean age 8.33 (range 6–12) years at the time of HSPN diagnosis with nephrotic-range proteinuria, were treated with MMF. All patients failed steroid treatment, and mean proteinuria at the time of MMF initiation was 5.6 g/d. MMF dosage ranged from 20 to 25 mg/kg per day. Patients also received an angiotensin-converting enzyme inhibitor (cliazapril) at MMF initiation. Mean follow-up was 3.9 (range 2.3–5.5) years.

Results

All patients responded to MMF at a mean of 2.5 (range 1–4 months). Among the 12 patients, MMF was administered for 10 months in five, 12 months in six, and 15 months in one. At last follow-up, all patients had negative proteinuria and normal renal function, and no relapses were noted. No serious adverse effects of MMF were noted in any patient.

Conclusion

MMF is useful for treating pediatric patients with HSPN and nephrotic-range proteinuria.

Keywords

Henoch–Schönlein nephritis Mycophenolate mofetil Nephrotic syndrome 

References

  1. 1.
    Lau KK, Suzuki H, Novak J, Wyatt RJ (2010) Pathogenesis of Henoch-Schönlein purpura nephritis. Pediatr Nephrol 25:19–26PubMedCrossRefGoogle Scholar
  2. 2.
    Ronkainen J, Ala-Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormälä T, Nuutinen M (2003) Outcome of Henoch-Schönlein nephritis with nephrotic-range proteinuria. Clin Nephrol 60:80–84PubMedGoogle Scholar
  3. 3.
    Shenoy M, Bradbury MG, Lewis MA, Webb NJ (2007) Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 22:1717–1722PubMedCrossRefGoogle Scholar
  4. 4.
    Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, Locatelli F, Cagnoli L (2006) Prediction of outcome in Henoch-Schönlein Nephritis in children and adults. Am J Kidney Dis 47:993–1003PubMedCrossRefGoogle Scholar
  5. 5.
    Zaffanello M, Brugnara M, Franchini M (2007) Therapy for children with Henoch-Schönlein purpura nephritis: a systematic review. Sci World J 7:20–30CrossRefGoogle Scholar
  6. 6.
    Ronkainen J, Autio-Harmainen H, Nuutinen M (2003) Cyclosporin A for the treatment of severe Henoch-Schönlein glomerulonephritis. Pediatr Nephrol 18:1138–1142PubMedCrossRefGoogle Scholar
  7. 7.
    Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Jeong HJ (2005) Henoch-Schönlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporine A and steroid treatment. Scand J Rheumatol 34:392–395PubMedCrossRefGoogle Scholar
  8. 8.
    Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Kim PK, Jeong HJ (2005) Can azathioprine and steroids alter the progression of severe Henoch-Schönlein nephritis in children? Pediatr Nephrol 20:1087–1092PubMedCrossRefGoogle Scholar
  9. 9.
    Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB (2001) Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose cooticosteroids plus oral cyclophosphamide. Am J Nephrol 21:128–133PubMedCrossRefGoogle Scholar
  10. 10.
    Kalliakmani P, Benou E, Goumenos DS (2011) Cyclosporin A in adult patients with Henoch-Schönlein purpura nephritis and nephrotic syndrome; 5 case reports. Clin Nephrol 75:380–383PubMedGoogle Scholar
  11. 11.
    Park JM, Won SC, Shin JI, Yim H, Pai KS (2011) Cyclosporin A therapy for Henoch-Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 26:411–417PubMedCrossRefGoogle Scholar
  12. 12.
    Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14(Suppl 1):S2–S8PubMedCrossRefGoogle Scholar
  13. 13.
    Flores-Suarez LF (2006) Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofeil. Arch Med Res 37:68–72PubMedCrossRefGoogle Scholar
  14. 14.
    Lenz O, Fornoni A, Contreras G (2005) Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. Drugs 65:2429–2436PubMedCrossRefGoogle Scholar
  15. 15.
    Bagga A, Hari P, Moudgil A, Jordan SC (2003) Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. Am J Kidney Dis 42:1114–1120PubMedCrossRefGoogle Scholar
  16. 16.
    Spetie DN, Tang Y, Rovin BH, Nadasdy G, Pesavento TE, Hebert LA (2004) Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 66:2411–2415PubMedCrossRefGoogle Scholar
  17. 17.
    Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, Ho YW, Lai KN (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68:802–812PubMedCrossRefGoogle Scholar
  18. 18.
    Borba EF, Guedes LK, Christmann RB, Figueiredo CP, Goncalves CR, Bonfa E (2006) Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 26:1078–1083PubMedCrossRefGoogle Scholar
  19. 19.
    Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF (2004) Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842–1849PubMedCrossRefGoogle Scholar
  20. 20.
    Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA, Gholizadeh A, Gholizadeh L (2010) Treatment of complicated henoch-schönlein purpura with mycophenolate mofetil: a retrospective case series report. Int J Rheumatol 2010:254316PubMedGoogle Scholar
  21. 21.
    Muzaffar M, Taj A, Sethi N, Kaw D (2010) Rapidly progressing glomerulonephritis secondary to henoch-Schönlein purpura treated with mycophenolate mofetil: a case report with atypical etiology and presentation. Am J Ther 17:e163–e166PubMedCrossRefGoogle Scholar
  22. 22.
    Dede F, Onec B, Ayli D, Gonul II, Onec K (2008) Mycophenolate mofetil treatment of crescentic Henoch-Schönlein nephritis with IgA depositions. Scand J Urol Nephrol 42:178–180PubMedCrossRefGoogle Scholar
  23. 23.
    Counahan R, Winterborn MH, White RHR, Heaton JM, Meadow SR, Bluett NH, Cameron JS, Chantler C (1977) Prognosis of Henoch-Schönlein nephritis in children. BMJ 2:11–14PubMedCrossRefGoogle Scholar
  24. 24.
    Sugiyama H, Watanabe N, Onoda T, Kikumoto Y, Yamamoto M, Maeta M, Ohara N, Maeshima Y, Yamasaki Y, Makino H (2004) Successful treatment of progressive Henoch-Schönlein purpura nephritis with tonsillectomy and steroid pulse therapy. Intern Med 44:611–615CrossRefGoogle Scholar
  25. 25.
    Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S (2003) Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 18:347–350PubMedGoogle Scholar
  26. 26.
    Deng F, Lu L, Zhang Q, Hu B, Xia X (2011) Improved Outcome of Henoch-Schönlein purpura nephritis by early intensive treatment. Indian J Pediatr. doi: 10.1007/s12098-011-0519-5
  27. 27.
    Wakaki H, Ishikura K, Hataya H, Hamasaki Y, Sakai T, Yata N, Kaneko T, Honda M (2011) Henoch-Schönlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol 26:921–925PubMedCrossRefGoogle Scholar
  28. 28.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945PubMedCrossRefGoogle Scholar
  29. 29.
    Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn K-H (1999) ACE inhibitor versus β-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 33:862–868PubMedGoogle Scholar
  30. 30.
    Fulton B, Markham A (1996) Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 51:278–298PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  • Yue Du
    • 1
    Email author
  • Ling Hou
    • 1
  • Chengguang Zhao
    • 1
  • Mei Han
    • 1
  • Yubin Wu
    • 1
  1. 1.Department of PediatricsShengjing hospital of China Medical UniversityShenyangChina

Personalised recommendations